Deloitte.

Crocus Investment Fund

March 31, 2017 Quarterly Report April 18, 2017

Table of contents

1.0	Background	1
2.0	Activities of the Receiver	2
3.0	Operations	3
4.0	Financial position	4
5.0	Portfolio	5
5.1	Background	5
5.2	Status	5
6.0	Commitments and contingencies	7
7.0	Share value	8
8.0	Interim distributions	9
8.1	First interim distribution	9
8.2	Second interim distribution	9
8.3	Third interim distribution	9
8.4	Unclaimed interim distributions	9
8.5	Future distributions	. 10
9.0	Shareholder communication	. 11
10.0	General	. 12
Appe	ndix 1 – Crocus financial information as at March 31, 2017	
Appe	endix 2 – Statement of receipts and disbursements to March 31, 2017	

1.0 Background

On June 28, 2005, pursuant to an application made by the Manitoba Securities Commission ("MSC") under Section 27 of The Securities Act, the Court of Queen's Bench of Manitoba (the "Court") made an Order (the "Receiving Order") appointing Deloitte Restructuring Inc. (formerly Deloitte & Touche Inc., hereafter referred to as "Deloitte" or the "Receiver") as Receiver and Manager of the Crocus Investment Fund ("Crocus" or the "Fund"). The Receiving Order appointed Deloitte as Receiver over all of Crocus' current and future assets, undertakings and properties and granted the Receiver powers to carry out its duties as outlined in the Receiving Order.

The purpose of this Report is to report on the activities of the Receiver as well as to provide an update on the financial position of the Fund. The Report will cover the Receiver's operations and activities since the December 31, 2016 Quarterly Report.

The financial information herein has not been audited and therefore the Receiver does not express any opinion on (a) the financial statements as of any date or for any period or (b) any financial data or other information referred to in this Report. The reader is cautioned that this Report may not disclose all matters and details about the ongoing Receivership proceedings. The Receiver assumes no responsibility or liability for any loss or damage occasioned by any party as a result of the circulation, publication, reproduction or use of this Report. Any use which any party makes of this Report, or any reliance or decision to be made based on this Report, is the sole responsibility of such party.

2.0 Activities of the Receiver

The following summarizes the major activities of the Receiver since December 31, 2016:

- Preparing the December 31, 2016 and March 31, 2017 Quarterly Reports;
- Administering the interim distributions of funds as outlined in the Court Orders of September 4, 2009, December 12, 2011, and October 14, 2014;
- Responding to shareholder inquiries resulting from letter correspondence dated December 9,
 2016 sent to all shareholders with any unclaimed funds from one (1) (or more) of the three (3) interim distributions, advising shareholders to claim these funds prior to February 28, 2017;
- Corresponding with numerous shareholders, brokers, dealers, and intermediaries regarding the distributions and status of the Fund:
- Supervising and directing agents retained by the Receiver;
- Meeting and corresponding with individual Crocus shareholders;
- Corresponding with the Fund's bare trustee to ensure that the creation of a new specimen plan in the event of death estate transfers and RRSP plan maturities are accepted by the Canada Revenue Agency;
- Ongoing monitoring and realization of the remaining investee companies and discussions with various stakeholders of the investees with respect to possible courses of action regarding Crocus' investment in the investees:
- Fulfilling the duties of Crocus as General Partner of the Manitoba Science & Technology Fund ("MS&T");
- Preparing and filing annual corporate tax returns;
- Preparing and distributing tax slips to shareholders; and
- Corresponding and meeting with the Receiver's counsel with respect to certain litigation with one of the investees.

3.0 Operations

The ongoing activities related to Crocus consist of investment monitoring, financial reporting, shareholder services, and tax reporting. The Receiver no longer employs any former employees of Crocus but has sub-contracted certain information technology and back office services.

4.0 Financial position

Financial information for Crocus has been prepared by the Receiver for the second fiscal quarter ended March 31, 2017, and is attached as Appendix 1.

The following are the more significant assets remaining in the Fund:

- Investments in cash and cash equivalents of approximately \$1.5 million. This excludes unclaimed funds of approximately \$2.2 million held in trust for shareholders relating to prior distributions; and
- Net carrying value of the remaining Crocus portfolio of investees of approximately \$5.2 million. The portfolio valuation is primarily carried at the June 28, 2005 value which was derived from the external valuations completed after Crocus ceased trading in December 2004.

5.0 Portfolio

5.1 Background

As at June 28, 2005, there were 46 individual investee companies in the Crocus portfolio with a gross carrying value of approximately \$64.1 million.

Cumulatively to March 31, 2017, 40 of the 46 investments within the Crocus portfolio have been realized upon or are considered closed.

In summary, since its appointment, the Receiver has realized proceeds of approximately \$60.4 million for investments with a June 28, 2005 book value of approximately \$58.9 million, representing a recovery of approximately 103%. Crocus' carrying value for these investments, when it ceased trading in December 2004, was approximately \$94.8 million, which would represent a recovery of approximately 64%. In addition, since its appointment, the Receiver has eliminated exposure on approximately \$2.3 million in guarantees that had been reserved by Crocus.

5.2 Status

The status of the remaining investments is as follows:

Novra Technologies Inc. ("Novra")

Novra is an investment held by the Fund representing both equity and debt obligations due to Crocus. The Receiver and the investee have entered into a long term agreement for the repayment of the indebtedness.

Manitoba Science & Technology Fund, Diamedica Inc., Genesys Ventures Inc., and ST Partnership

Crocus is an investor in MS&T which is a limited partnership holding several science and technology investments. Crocus is the sole owner of the General Partner and the limited partners gave the General Partner a mandate to wind down the partnership. Crocus and MS&T's holdings include Diamedica Inc., Genesys Ventures Inc., and ST Partnership. There are numerous interrelationships amongst these entities. In some cases, the ability to negotiate divestitures of MS&T's science and technology investments is limited given that certain of the companies are publicly traded with limited market liquidity. As a result, the timing of a complete disposition is unknown.

Canad Corporation Ltd. ("Canad")

On June 19, 2014, the Receiver caused Crocus to commence proceedings against Leon Norman Ledohowski ("Leo"), LRC Holding Corporation Inc., and Canad Corporation Ltd. ("Canad") as Respondents in a Court of Queen's Bench filing. In its Notice of Application, Crocus sought various forms of relief including declarations that Leo had exercised his powers as a director of Canad, and that Canad had conducted its business and affairs in a manner that was oppressive of, or unfairly prejudicial to, or which unfairly disregarded, the interests of Crocus as a shareholder of Canad. The Notice of Application also sought an Order that Canad be liquidated and dissolved and that the proceeds from such liquidation be distributed to the shareholders of Canad. The Notice of Application was supported by an Affidavit sworn by Steven P. Peleck (the "Peleck Affidavit"), in his capacity as Senior Vice-President of the Receiver. Counsel for Canad filed a motion seeking an

order expunging certain parts of the Peleck Affidavit. The motion was heard on May 27, 2015 and, during submissions before Madam Justice Pfeutzner, it was agreed that the Notice of Application and Affidavit would be expunged with leave to file amended documents.

On July 17, 2015, an Amended Notice of Application was filed seeking various forms of relief including declarations that Leo had exercised his powers as a director of Canad and that Canad had conducted its business and affairs in a manner that was oppressive of, or unfairly prejudicial to, or which unfairly disregarded, the interest of Crocus as a shareholder of Canada. The Amended Notice of Application also sought an Order that Canad be liquidated and dissolved and that the proceeds from such liquidation be distributed to the shareholders of Canad. The Amended Notice of Application was supported by an Affidavit sworn by Brent Warga (the "Warga Affidavit"), in his capacity as Senior Vice-President of the Receiver. The Respondents filed affidavit evidence on May 31, 2016. Cross-examinations on affidavits, which were rescheduled from March 2016 to May 2016 at the request of the Respondents, did not occur and new cross-examination dates have not yet been determined.

On September 12, 2016, the Receiver, along with its legal counsel, met with Canad to revisit whether an exit strategy for Crocus could be mutually agreed upon. Although continued dialogue between the Receiver and Canad did occur subsequent to this meeting, an exit strategy was not reached and the litigation proceedings continue.

6.0 Commitments and contingencies

The only remaining known contingency relates to an indemnity provided by Crocus to an investee company. This indemnity does not create a requirement for Crocus to fund the investee but does potentially alter the rights of Crocus and other shareholders of the investee.

7.0 Share value

The estimated net asset value of the Class A and Class I shares (the "Share Value") as at March 31, 2017 was \$0.47 per share, as detailed in Appendix 1. As noted in previous reports, the Receiver emphasizes that the Share Value is an accounting book value partially based on the June 28, 2005 carrying value of the investment portfolio.

Future events will determine the ultimate realizable value of the portfolio. Such matters may have a material effect on the Share Value which is ultimately available for distribution to Crocus shareholders. The future events identified to date include:

- Possible further increases/reductions in the value of the portfolio as a result of ongoing investee performance;
- The length of time it takes to realize on the portfolio;
- Professional costs incurred by the Receiver and its counsel as a result of current and future negotiations and litigation;
- Any additional guarantees or indemnities granted by Crocus which have not yet been identified; and/or
- All other costs of monitoring the portfolio and realizing on the assets.

The Receiver will continue to provide updates on the Share Value in future Quarterly Reports.

8.0 Interim distributions

8.1 First interim distribution

On September 4, 2009, the Court issued an Order authorizing a rateable interim distribution of approximately \$54.7 million to the Class A and Class I shareholders. Concurrent with the distribution, the Receiver also began distributing the net proceeds of the Class Actions settlements in the amount of approximately \$6.8 million. Class A and Class I shareholders received \$3.83 per share from the approved distribution plus their portion of the Class Actions settlements.

As at March 31, 2017, the Receiver had paid out approximately \$53.6 million, or approximately 98%, of the first interim distribution, and approximately \$6.7 million of the Class Actions settlements. There remains approximately \$1.2 million in unclaimed distributions.

8.2 Second interim distribution

On December 12, 2011, the Court issued an Order authorizing a second interim distribution of approximately \$9.0 million to the Class A and Class I shareholders.

Mailings for the distribution took place in January 2012. As at March 31, 2017, the Receiver had paid out approximately \$8.6 million, or 96%, of the second interim distribution, however, there remains approximately \$0.4 million in unclaimed distributions.

8.3 Third interim distribution

On October 14, 2014, the Court issued an Order authorizing a third interim distribution of \$0.60 per share to the Class A and Class I shareholders, or approximately \$8.6 million. Concurrent with the distribution, the Receiver also distributed the remaining Class Actions settlements proceeds of approximately \$0.7 million.

Mailings for the distribution took place in October and November 2014. As at March 31, 2017, the Receiver had paid out approximately \$8.0 million, or 93%, of the third interim distribution and approximately \$0.6 million of the remaining Class Actions settlements. There remains approximately \$0.6 million in unclaimed distributions.

8.4 Unclaimed interim distributions

On December 9, 2016, the Receiver sent correspondence to all shareholders with any unclaimed funds from one (1) or more of the three (3) interim distributions. The correspondence was customized for each shareholder depending on the nature of the account held and the funds that remained unclaimed. The Receiver requested that shareholders follow the detailed instructions in the correspondence to claim their distribution entitlements at their earliest opportunity, and by no later than February 28, 2017. Shareholders were further advised that any funds remaining unclaimed subsequent to February 28, 2017 may be paid to the Minister of Finance, following which shareholders will be obligated to prove their entitlement to the funds.

In total 6,690 letters were sent to shareholders with unclaimed funds. Responses were received from approximately 34% (2,307) of these shareholders resulting in approximately \$1.2M in funds being distributed.

8.5 Future distributions

The majority of the Crocus assets have been realized upon with net proceeds of approximately \$72.3 million being approved by the Court for distribution to the Crocus shareholders. In addition, shareholders have been paid their portions of the Class Actions settlements and the Class Actions have been finalized.

As noted above, the Receiver currently has approximately \$1.5 million of cash and cash equivalents available to fund shareholder services operations and to continue to realize on the remaining six (6) investments. Given the illiquidity of the remaining investments, as well as the ongoing litigation with Canad, the Receiver is of the view that any future distribution will be based on the settlement or outcome of the Canad litigation. Accordingly, the Receiver is unable to determine when, or if, any future distributions will take place.

9.0 Shareholder communication

The Receiver has continued to post Court Orders, Receiver's Reports, Quarterly Reports, media statements and shareholder letters on its website at www.deloitte.com/ca/crocusfund.

10.0 General

A Statement of Receipts and Disbursements for the period from June 28, 2005 to March 31, 2017 is attached as Appendix 2.

The Receiver will continue to keep the Court apprised of ongoing developments with the next Quarterly Report to be filed in mid-July 2017.

Respectfully submitted this 18th day of April, 2017.

DELOITTE RESTRUCTURING INC., in its capacity as Receiver and Manager of Crocus Investment Fund and not in its

personal capacity.

Per: Brent Warga

Senior Vice-President

Appendix 1 – Crocus financial information as at March 31, 2017

Crocus Investment Fund Consolidated Statement of Net Assets As at March 31, 2017 (unaudited)

ASSETS	Mar	ch 31, 2017	
Cash and equivalents	\$	1,467,546	
Cash in Trust - Unclaimed Interim Distributions		2,235,174	
Investments in Manitoba businesses		5,180,926	
		8,883,646	
Accounts receivable		22,832	
Capital assets	8,906,478		
LIABILITIES			
Accounts payable and accrued liabilities		23,463	
Due to Shareholders - Unclaimed Interim Distributions		2,235,174	
NET ASSETS	\$	6,647,841	
SHAREHOLDERS' EQUITY			
Share capital	\$	188,014,669	
Deferred selling costs adjustment		(9,134,637)	
Interim Distributions - Class "A" shares		(71,951,299)	
Interim Distributions - Class "I" shares		(349,770)	
Interim Distributions - Class "L" shares		(200)	
Deficit		(99,930,922)	
	\$	6,647,841	
NET ASSET VALUE PER SHARE			
Net assets	\$	6,647,841	
Balance attributed to the Class "A" Common and Series Two Class "I" Special Shares	\$	6,647,841	
Number of issued Class "A" Common Shares		14,220,000	
Number of issued Series Two Class "I" Special Shares		69,126	
		14,289,126	
NET ASSET VALUE PER CLASS "A" COMMON SHARE and SERIES TWO CLASS "I" SPECIAL SHARE	\$	0.47	

Crocus Investment Fund Consolidated Statement of Investment Portfolio As at March 31, 2017 (unaudited)

INVESTMENTS IN MANITOBA BUSINESSES

Canad Corporation of Canada Inc.

Diamedica Inc.

Genesys Venture Inc.

Manitoba Science & Technology Fund

Novra Technologies Inc.

ST Partnership

INVESTMENTS IN MANITOBA BUSINESSES

5,180,926

\$

Appendix 2 – Statement of receipts and disbursements to March 31, 2017

	June 28, 2005 to <u>March 31, 2016</u>		April 1, 2016 to <u>March 31, 2017</u>		<u>Total</u>	
Receipts						
Cash and Short Term Investments on Hand	\$	23,363,012	\$	-	\$	23,363,012
Contract Back Office Services		518,463		-		518,463
Dividends-Portfolio		657,483		_		657,483
Income Tax Refund		520,196		7,682		527,878
Insurance Claim and Premium Refund		20,662				20,662
Interest-Portfolio		1,929,765		38,442		1,968,207
Interest-Fortion Interest-Short Term Investments		7,727,235		14,501		
						7,741,736
Investment Principal Repayments		3,182,022		81,557		3,263,579
Management Fees		1,295,043		44,132		1,339,175
Proceeds on Disposal of Investments		57,140,767		22,970		57,163,737
Rent/Sub-Lease		2,671,548		-		2,671,548
Sundry		301,676		-		301,676
Pre-Receivership Accounts Receivable		1,247,463		_		1,247,463
Class Action Settlements		7,494,924		_		7,494,924
oldss Action Settlements	-	7,474,724				7,474,724
Total Receipts	\$	108,070,259	\$	209,284	\$_	108,279,543
Disbursements						
Advances to Investees	\$	265,132	\$	-	\$	265,132
Capital Tax		200,257		-		200,257
Computer, Telephone and Office Expense		856,301		5,504		861,805
Consulting Fees		359,150		-		359,150
Employee Pension		442,922		_		442,922
Insurance - Indemnification		167,563		_		167,563
Investee Guarantee and Indemnification		1,344,677				1,344,677
				2 (05		
Investment Expenses		223,133		2,685		225,818
Legal Fees		2,292,238		45,150		2,337,388
Disbursements		64,678		1,460		66,138
Taxes		294,107		5,929		300,036
Legal Fees - Indemnification		728,405		-		728,405
Disbursements		12,985		-		12,985
Taxes		59,311		_		59,311
Payroll & Benefits		1,735,550		_		1,735,550
Receiver and Manager Fees		8,804,347		228,802		9,033,149
Taxes		491,554		11,572		503,126
Rent		4,317,703		-		4,317,703
Settlements		775,991		-		775,991
Shareholder Services		2,164,467		213,454		2,377,921
Pre-Receivership Payables and Accruals	-	914,385		-		914,385
Total Disbursements		26,514,856		514,556		27,029,412
Excess (Shortfall) of Receipts over Disbursements prior to:		81,555,403		(305,272)		81,250,131
Interim Distributions - Class "A" Shares		68,782,103		1,102,512		69,884,615
Interim Distributions - Class "I" & "L" Shares		349,970		· -		349,970
Class Action Settlements		7,222,807		90,019		7,312,826
Excess (Shortfall) of Receipts over Disbursements	\$	5,200,523	\$	(1,497,803)	\$	3,702,720
Represented by:						
Short Term Investments and Bonds					\$	1,467,546
Cash in Trust - Unclaimed Interim Distributions					_	2,235,174
					\$	3,702,720

Deloitte.

www.deloitte.ca

Deloitte, one of Canada's leading professional services firms, provides audit, tax, consulting, and financial advisory services. Deloitte LLP, an Ontario limited liability partnership, is the Canadian member firm of Deloitte Touche Tohmatsu Limited.

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte Touche Tohmatsu Limited and its member firms.